Reneo Pharmaceuticals stockholders approval merger with OnKure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2024
0mins
Merger Announcement: Reneo Pharmaceuticals' stockholders approved the merger with OnKure, Inc., expected to close around October 4, 2024, after which the company will be renamed OnKure Therapeutics, Inc. and trade under the ticker "OKUR" on Nasdaq.
Management and Focus: The new entity will be led by OnKure's management and will concentrate on developing treatments targeting PI3Kalpha mutations, including its lead program OKI-219 currently in Phase 1 trials for solid tumors, alongside a 1-for-10 reverse stock split.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
